withaferin-a and Liver-Diseases--Alcoholic

withaferin-a has been researched along with Liver-Diseases--Alcoholic* in 1 studies

Other Studies

1 other study(ies) available for withaferin-a and Liver-Diseases--Alcoholic

ArticleYear
Withaferin A alleviates ethanol-induced liver injury by inhibiting hepatic lipogenesis.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2022, Volume: 160

    Withaferin A (WA) is a natural steroidal compound with reported hepatoprotective activities against various liver diseases. Whether WA has therapeutic effects on alcoholic liver disease has not been explored. A binge alcoholic liver injury model was employed by feeding C57BL/6J mice an ethanol (EtOH) diet for 10 days followed by an acute dose of EtOH to mimic clinical acute-upon-chronic liver injury. In this binge model, WA significantly reduced the binge EtOH-induced increase of serum aminotransaminase levels and decreased hepatic lipid accumulation. Mechanistically, WA decreased levels of hepatic lipogenesis gene mRNAs in vivo, including Srebp1c, Fasn, Acc1 and Fabp1. In EtOH-treated primary hepatocytes in vitro, WA decreased lipid accumulation by lowering the expression of the lipogenesis gene mRNAs Fasn and Acc1 as well as decreasing hepatocyte death. In the established binge alcoholic liver injury model, WA therapeutically reduced the EtOH-induced increase of serum aminotransaminase levels as well as hepatic lipid accumulation. These results demonstrate that WA reduces EtOH-induced liver injury by inhibiting hepatic lipogenesis, suggesting a potential therapeutic option for treating alcoholic liver injury.

    Topics: Acetyl-CoA Carboxylase; Animals; Cell Death; Ethanol; Fatty Acid Synthase, Type I; Female; Hepatocytes; Humans; Lipid Metabolism; Lipogenesis; Liver; Liver Diseases, Alcoholic; Male; Mice; Mice, Inbred C57BL; Sterol Regulatory Element Binding Protein 1; Withanolides

2022